Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis
Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight
Hello, and thank you for visiting the AIKTC-KRRC News Page. If you have any questions regarding the AIKTC-KRRC, please comment below, find us at facebook.com/AIKTCCentralLibrary/, or contact us at 022-27481247/48, or librarian@aiktc.ac.in